
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1762652/publications.pdf Version: 2024-02-01



KIIDT F HEDSREDCED

#	Article	IF	CITATIONS
1	Inappropriate prescribing: a systematic overview of published assessment tools. European Journal of Clinical Pharmacology, 2014, 70, 1-11.	1.9	190
2	Pharmaceutical Care: the PCNE definition 2013. International Journal of Clinical Pharmacy, 2014, 36, 544-555.	2.1	142
3	PCNE definition of medication review: reaching agreement. International Journal of Clinical Pharmacy, 2018, 40, 1199-1208.	2.1	137
4	A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes. Frontiers in Pharmacology, 2018, 9, 1290.	3.5	118
5	Determination of risk factors for drug-related problems: a multidisciplinary triangulation process. BMJ Open, 2015, 5, e006376-e006376.	1.9	102
6	Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. International Journal of Clinical Pharmacy, 2013, 35, 1130-1136.	2.1	80
7	Provision of pharmaceutical care by community pharmacists: a comparison across Europe. International Journal of Clinical Pharmacy, 2010, 32, 472-487.	1.4	77
8	Impact of a community pharmacist-led medication review on medicines use in patients on polypharmacy - a prospective randomised controlled trial. BMC Health Services Research, 2016, 16, 145.	2.2	77
9	Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial. Respiratory Research, 2018, 19, 237.	3.6	72
10	Proposal of Standardization to Assess Adherence With Medication Records. Annals of Pharmacotherapy, 2016, 50, 360-368.	1.9	68
11	Provision of pharmaceutical care by community pharmacists across <scp>E</scp> urope: Is it developing and spreading?. Journal of Evaluation in Clinical Practice, 2017, 23, 1336-1347.	1.8	61
12	Effect of drug reminder packaging on medication adherence: a systematic review revealing research gaps. Systematic Reviews, 2014, 3, 29.	5.3	53
13	A method for calculating adherence to polypharmacy from dispensing data records. International Journal of Clinical Pharmacy, 2014, 36, 192-201.	2.1	49
14	Classification of drug-related problems with new prescriptions using a modified PCNE classification system. International Journal of Clinical Pharmacy, 2010, 32, 362-372.	1.4	47
15	Matching Adherence Interventions to Patient Determinants Using the Theoretical Domains Framework. Frontiers in Pharmacology, 2016, 7, 429.	3.5	47
16	Sequential screening for diabetes—evaluation of a campaign in Swiss community pharmacies. International Journal of Clinical Pharmacy, 2006, 28, 171-179.	1.4	40
17	Community pharmacist-led medication review procedures across Europe: Characterization, implementation and remuneration. Research in Social and Administrative Pharmacy, 2020, 16, 1057-1066.	3.0	34
18	The 8â€item <scp>M</scp> orisky <scp>M</scp> edication <scp>A</scp> dherence <scp>S</scp> cale translated in <scp>G</scp> erman and validated against objective and subjective polypharmacy adherence measures in cardiovascular patients. Journal of Evaluation in Clinical Practice, 2015, 21, 271-277.	1.8	33

#	Article	IF	CITATIONS
19	Needs and use of drug information sources in community pharmacies: a questionnaire based survey in German-speaking Switzerland. International Journal of Clinical Pharmacy, 2004, 26, 197-202.	1.4	32
20	Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review. Journal of Clinical Epidemiology, 2017, 91, 70-79.	5.0	31
21	Development of Clinical Pharmacy in Switzerland: Involvement of Community Pharmacists in Care for Older Patients. Drugs and Aging, 2016, 33, 205-211.	2.7	30
22	Polymedication Electronic Monitoring System (POEMS) – a new technology for measuring adherence. Frontiers in Pharmacology, 2013, 4, 26.	3.5	27
23	Adherence counseling during patient contacts in Swiss community pharmacies. Patient Preference and Adherence, 2015, 9, 597.	1.8	27
24	Demonstrating the clinical pharmacist's activity: validation of an intervention oriented classification system. International Journal of Clinical Pharmacy, 2015, 37, 1162-1171.	2.1	24
25	Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial. Respiratory Research, 2019, 20, 273.	3.6	24
26	Change of body weight and lifestyle of persons at risk for diabetes after screening and counselling in pharmacies. International Journal of Clinical Pharmacy, 2008, 30, 222-226.	1.4	22
27	Dispensing of Prescribed Medicines in Swiss Community Pharmacies-Observed Counselling Activities. Pharmacy (Basel, Switzerland), 2019, 7, 1.	1.6	22
28	A survey to assess the availability, implementation rate and remuneration of pharmacist-led cognitive services throughout Europe. Research in Social and Administrative Pharmacy, 2020, 16, 41-47.	3.0	22
29	Risk Factors Associated with a High Velocity of the Development of Hyperkalaemia in Hospitalised Patients. Drug Safety, 2007, 30, 71-80.	3.2	21
30	Management of potential drug interactions in community pharmacies: a questionnaire-based survey in Switzerland. European Journal of Clinical Pharmacology, 2007, 63, 297-305.	1.9	21
31	Dose-dispensing service as an intervention to improve adherence to polymedication. Expert Review of Clinical Pharmacology, 2013, 6, 413-421.	3.1	21
32	White coat effect and white coat hypertension in community pharmacy practice. Blood Pressure Monitoring, 2005, 10, 13-18.	0.8	19
33	Hospital discharge: What are the problems, information needs and objectives of community pharmacists? A mixed method approach. Pharmacy Practice, 2017, 15, 1046-1046.	1.5	17
34	Validation of a Novel Electronic Device for Medication Adherence Monitoring of Ambulatory Patients. Pharmacy (Basel, Switzerland), 2019, 7, 155.	1.6	16
35	The ABC taxonomy for medication adherence translated into French and German. British Journal of Clinical Pharmacology, 2020, 86, 734-744.	2.4	16
36	Mapping clinical pharmacy practice in Swiss hospitals: a cross-sectional study. European Journal of Hospital Pharmacy, 2016, 23, 314-319.	1.1	15

#	Article	IF	CITATIONS
37	Translation and validation of a tool to assess the impact of clinical pharmacists' interventions. International Journal of Clinical Pharmacy, 2019, 41, 56-64.	2.1	14
38	Impact of an Electronic Monitoring Intervention to Improve Adherence to Inhaled Medication in Patients with Asthma and Chronic Obstructive Pulmonary Disease: Study Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2017, 6, e204.	1.0	14
39	Swallowing difficulties with medication intake assessed with a novel self-report questionnaire in patients with systemic sclerosis – a cross-sectional population study. Patient Preference and Adherence, 2017, Volume 11, 1687-1699.	1.8	13
40	Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study. Journal of Thrombosis and Thrombolysis, 2020, 49, 606-617.	2.1	13
41	Drug-Associated Risk Tool: development and validation of a self-assessment questionnaire to screen for hospitalised patients at risk for drug-related problems. BMJ Open, 2018, 8, e016610.	1.9	12
42	Humanistic outcomes and patient acceptance of the pharmacist-led medication review "Polymedication Check" in primary care in Switzerland: a prospective randomized controlled trial. Patient Preference and Adherence, 2018, Volume 12, 1071-1078.	1.8	12
43	Drug-related problems in diabetes and transplant patients: an observational study with home visits. International Journal of Clinical Pharmacy, 2011, 33, 815-823.	2.1	11
44	Assessing the ability of the Drug-Associated Risk Tool (DART) questionnaire to stratify hospitalised older patients according to their risk of drug-related problems: a cross-sectional validation study. BMJ Open, 2018, 8, e021284.	1.9	11
45	Emergency hormonal contraception in Switzerland: A comparison of the user profile before and three years after deregulation. European Journal of Contraception and Reproductive Health Care, 2009, 14, 349-356.	1.5	10
46	Issues around the Prescription of Half Tablets in Northern Switzerland: The Irrational Case of Quetiapine. BioMed Research International, 2015, 2015, 1-8.	1.9	10
47	Documentation of pharmaceutical care: development of an intervention oriented classification system. International Journal of Clinical Pharmacy, 2017, 39, 354-363.	2.1	10
48	Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report. International Journal of Molecular Sciences, 2021, 22, 6480.	4.1	9
49	Assessing Medication Adherence Barriers to Short-Term Oral Antibiotic Treatment in Primary Care—Development and Validation of a Self-Report Questionnaire (BIOTICA). International Journal of Environmental Research and Public Health, 2021, 18, 7768.	2.6	9
50	Pattern of Timing Adherence Could Guide Recommendations for Personalized Intake Schedules. Journal of Personalized Medicine, 2012, 2, 267-276.	2.5	8
51	Patient views on an electronic dispensing device for prepackaged polypharmacy: a qualitative assessment in an ambulatory setting. Integrated Pharmacy Research & Practice, 2015, 4, 167.	1.5	8
52	The Integrated Care of Asthma in Switzerland (INCAS) Study: Changes in Asthma Control and Perception of Health Care through Asthma Education. Respiration, 2017, 94, 416-423.	2.6	8
53	Do Swiss community pharmacists address the risk of sexually transmitted infections during a consultation on emergency contraception? A simulated patient study. European Journal of Contraception and Reproductive Health Care, 2019, 24, 407-412.	1.5	8
54	A RCT evaluating a pragmatic in-hospital service to increase the quality of discharge prescriptions. International Journal for Quality in Health Care, 2019, 31, G74-G80.	1.8	8

#	Article	IF	CITATIONS
55	Patient Knowledge about Oral Anticoagulation Therapy Assessed during an Intermediate Medication Review in Swiss Community Pharmacies. Pharmacy (Basel, Switzerland), 2020, 8, 54.	1.6	8
56	Insights Into Direct Oral Anticoagulant Therapy Implementation of Stroke Survivors with Atrial Fibrillation in an Ambulatory Setting. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105530.	1.6	8
57	Nonresponse to high-dose bupropion for depression in a patient carrying <i>CYP2B6</i> *6 and <i>CYP2C19</i> *17 variants: a case report. Pharmacogenomics, 2020, 21, 1145-1150.	1.3	8
58	Success of a sustained pharmaceutical care service with electronic adherence monitoring in patient with diabetes over 12 months. BMJ Case Reports, 2015, 2015, bcr2014208672-bcr2014208672.	0.5	7
59	Stability of medicines after repackaging into multicompartment compliance aids: eight criteria for detection of visual alteration. Drugs and Therapy Perspectives, 2017, 33, 487-496.	0.6	7
60	Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial. Trials, 2021, 22, 919.	1.6	7
61	Pharmacogenetic-Guided Antidepressant Selection as an Opportunity for Interprofessional Collaboration: A Case Report. Life, 2021, 11, 673.	2.4	6
62	Multidrug punch cards in primary care: a mixed methods study on patients' preferences and impact on adherence. Frontiers in Pharmacology, 2014, 5, 220.	3.5	5
63	Protocol for MAAESTRO: Electronic Monitoring and Improvement of Adherence to Direct Oral Anticoagulant Treatment—A Randomized Crossover Study of an Educational and Reminder-Based Intervention in Ischemic STROke Patients Under Polypharmacy. Frontiers in Neurology, 2018, 9, 1134.	2.4	5
64	Translation to English, cross-cultural adaptation, and pilot testing of the self-report questionnaire on swallowing difficulties with medication intake and coping strategies (SWAMECO) for adults with polypharmacy. BMJ Open, 2020, 10, e036761.	1.9	5
65	Impact of the COVID-19 lockdown on the adherence of stroke patients to direct oral anticoagulants: a secondary analysis from the MAAESTRO study. Journal of Neurology, 2022, 269, 19-25.	3.6	5
66	Wrongly Prescribed Half Tablets in a Swiss University Hospital. International Journal of Clinical Medicine, 2012, 03, 637-643.	0.2	5
67	Antiplatelet resistance in outpatients with monitored adherence. Platelets, 2014, 25, 532-538.	2.3	4
68	Readiness of pharmacists and consumers for pharmacy-based chlamydia screening in Australia and Switzerland. Sexual and Reproductive Healthcare, 2018, 16, 138-153.	1.2	4
69	Contribution of Patient Interviews as Part of a Comprehensive Approach to the Identification of Drug-Related Problems on Geriatric Wards. Drugs and Aging, 2018, 35, 665-675.	2.7	4
70	Medication Discrepancies in Community Pharmacies in Switzerland: Identification, Classification, and Their Potential Clinical and Economic Impact. Pharmacy (Basel, Switzerland), 2020, 8, 36.	1.6	4
71	Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 279-286.	0.7	4
72	Pharmacogenetics in Pharmaceutical Care—Piloting an Application-Oriented Blended Learning Concept. Pharmacy (Basel, Switzerland), 2021, 9, 152.	1.6	4

#	Article	IF	CITATIONS
73	Clinical Pharmacy Activities in Swiss Hospitals: How Have They Evolved from 2013 to 2017?. Pharmacy (Basel, Switzerland), 2020, 8, 19.	1.6	4
74	Case report: Non-response to fluoxetine in a homozygous 5-HTTLPR S-allele carrier of the serotonin transporter gene. Frontiers in Psychiatry, 0, 13, .	2.6	4
75	Development and validation of a questionnaire to self-assess patient knowledge of direct oral anticoagulants (KODOA-test). Drug, Healthcare and Patient Safety, 2018, Volume 10, 69-77.	2.5	3
76	Pharmaceutical Discharge Management: Implementation in Swiss Hospitals Compared to International Guidelines. Pharmacy (Basel, Switzerland), 2021, 9, 33.	1.6	3
77	Economic evaluation of a novel genetic screening test for risk of venous thromboembolism compared with standard of care in women considering combined hormonal contraception in Switzerland. BMJ Open, 2019, 9, e031325.	1.9	2
78	Who Is Best to Test? A Systematic Review of Chlamydia Infections in Switzerland. International Journal of Environmental Research and Public Health, 2020, 17, 9389.	2.6	2
79	How do elderly outpatients manage polypharmacy including DOAC - A qualitative analysis highlighting a need for counselling. Research in Social and Administrative Pharmacy, 2022, 18, 3019-3026.	3.0	2
80	Communicating Electronic Adherence Data to Physicians—Consensus-Based Development of a Compact Reporting Form. International Journal of Environmental Research and Public Health, 2021, 18, 10264.	2.6	2
81	Detection and resolution of drug-related problems at hospital discharge focusing on information availability – a retrospective analysis. Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen, 2021, 166, 18-26.	0.9	2
82	Benefits of medication charts provided at transitions of care: a narrative systematic review. BMJ Open, 2020, 10, e037668.	1.9	2
83	Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 465-475.	0.7	2
84	Medication Review and Medication Reconciliation. , 2019, , 69-87.		1
85	Development and testing of a framework for defining a strategy to address medication adherence during patient encounters in community pharmacies. Exploratory Research in Clinical and Social Pharmacy, 2022, 5, 100123.	1.0	1
86	Authors' reply. Pharmacy Practice, 2017, 15, 1148-1148.	1.5	0
87	A survey on what pharmacists and physicians caring for nursing home residents expect of user-friendly lists of potentially inappropriate prescribing (PIP lists). Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen, 2020, 155, 29-33.	0.9	ο
88	Paying for Pharmaceutical Care. , 2019, , 461-466.		0
89	Benefits of medication charts provided at transitions of care: a narrative systematic review. BMJ Open, 2020, 10, e037668.	1.9	0
90	Delta T, a Useful Indicator for Pharmacy Dispensing Data to Monitor Medication Adherence. Pharmaceutics, 2022, 14, 103.	4.5	0